MADRID, Dec. 10th. (EUROPA PRESS) –
The single medical treatment of trastuzumab emtansin, registered by Roche under the name "Kadcyla", reduces the risk of disease recurrence or death by 50 percent compared to trastuzumab (& Herceptin) as adjuvant treatment (after surgery) in patients with early HER2 positive breast cancer with residual disease (pathological invasive residual disease in breast and / or axillary lymph nodes) following neoadjuvant treatment, according to the results of the Katherine phase III study.
In three years, 88.3 percent of patients treated with & # 39; Kadcyla & # 39; not a relapse compared with 77 percent, which had received & # 39; Herceptin & # 39 ;, representing an improvement of 11.3 percent.
Additionally, & # 39; Kadcyla & # 39; survival free of invasive disease, regardless of status of the hormone receptor and lymph nodes, as well as the previous therapeutic regimen against HER2 received prior to surgery.
"The results of this study show a significant reduction in the risk of relapse of this type of early breast cancer in people with residual disease after neoadjuvant therapy and we plan to send this data to the health authorities as soon as possible. With each of these advances that reduce the recurrence of the disease, we closer and closer to the goal of helping each patient with early breast cancer to get a greater chance of healing, "says the senior doctor and responsible of Global Product Development at Roche, Sandra Horning.
These results have been presented recently in an oral session at the San Antonio Breast Cancer Symposium as part of the Congressional Official Press Program and have been published simultaneously in The New England Journal of Medicine (NEJM).